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ABSTRACT 
Racemic ketorolac clearance is significantly higher at delivery, but S-ketorolac disposition 
determines the analgesic effects. To document the impact of pregnancy and postpartum on 
enantiomer-specific (S and R) ketorolac pharmacokinetics (PK) in young women, observations 
shortly following caesarean delivery (n=39) were pooled with data in subgroup of these women 
(n=8/39) four months afterwards (‘postpartum’) and with 8 healthy female volunteers, resulting  
in 47 unpaired and 8 paired PK estimates. All women received single intravenous bolus of 
ketorolac tromethamine (30 mg). Five (at 1, 2, 4, 6, 8 h) plasma samples were collected and 
plasma concentrations were determined using HPLC method. Enantiomer-specific PKs were 
calculated using PKSolver. Unpaired analysis documented that distribution volume at steady 
state (Vss, L/kg) for S- and R-ketorolac was significantly higher in women following delivery  
(n=31) compared to postpartum (n=8) or to healthy female volunteers (n=8). Clearance (CL), CL 
to body weight (CL/BW) and CL to body surface area (CL/BSA) for S- and R-ketorolac were 
also significantly higher following delivery. In addition, S/R-ketorolac CL/BSA ratio was 
significantly higher at delivery. Paired PK analysis in 8 women following delivery or postpartum 
showed the same pattern. Finally, the simultaneous increase in CL and Vss resulted in similar 
estimates for elimination half-life in both unpaired and paired analysis. In conclusion, pregnancy 
affects S-, R-, and S/R-ketorolac disposition. This is of clinical relevance since S-ketorolac 
(analgesia) CL is even more increased compared to R-ketorolac CL and S/R-ketorolac CL ratio 
is higher following delivery compared to postpartum or to healthy female volunteers. 
KEYWORDS: pharmacokinetics, ketorolac, enantiomers, pregnancy, caesarean delivery, 
postpartum 
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INTRODUCTION 
Ketorolac is a potent non-steroidal anti-inflammatory drug. It is a chiral substance comprising of 
S (-) and R (+) enantiomers. Although those ketorolac enantiomers comes in equal portions [1], 
pharmacological activity, being almost exclusively attributed to S-ketorolac [2-6], makes 
enantiomer-specific ketorolac pharmacokinetics of clinical relevance. 
 
Stereoselectivity has been described for binding to plasma albumin as well as for metabolism. 
Stereoselective binding to plasma albumin, which is lower for S- (98.4%) than for R-ketorolac 
(99.2%) [3], can explain enantiomer-specific pharmacokinetic (PK) differences [7,8]. In 
addition, stereoselective ketorolac metabolisation, mainly by uridine-diphosphate-glucuronosyl-
transferase (UGT)2B7 and higher for S- than for R-ketorolac, has also been documented [9]. As 
a consequence of those important stereoselective processes, a 4-5 fold higher distribution volume 
and clearance as well as twice shorter elimination half-life (2.5 vs 5 hours) has been documented 
for S- compared to R-ketorolac [10,11]. The S/R-ketorolac %AUC (area under the time versus 
concentration curve) after intravenous (IV) administration in adult patients is 0.36, independent 
of the administered dose [3]. 
 
Ketorolac is frequently used as analgesic drug in pregnancy and in postpartum [12-18]. 
Physiological changes in pregnancy and postpartum (e.g. changes in total body water, plasma 
volume, plasma albumin levels, cardiac output, drug-metabolizing enzymes and drug transport, 
kidney filtration) have been repeatedly shown to affect pharmacokinetics of many drugs [19,20]. 
A higher free drug fraction in pregnancy is suggested to facilitate both extraction in the liver and 
primary renal elimination [21]. Furthermore, the increase in in vivo phenotypic oxidation 
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(CYP2C8-9) [9,22,23] and UGT2B7 activity during pregnancy [9], as well as different routes of 
elimination during pregnancy compared to those in postpartum and in healthy female volunteers 
are also suggested [24].  
 
Despite the frequent and off-label use of ketorolac in pregnancy and in postpartum [12-18], no 
data on the impact of pregnancy and postpartum on enantiomer-specific ketorolac 
pharmacokinetic parameters are available. Therefore, the aim of our study was to document the 
impact of pregnancy and postpartum on enantiomer-specific ketorolac pharmacokinetic 
parameters after a single IV ketorolac bolus.  
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MATERIALS AND METHODS  
Ethics and study registration  
The study was approved by the Ethics Committee of the University Hospitals Leuven (internal 
study number 53048). Written informed consent was obtained from all women. The study was 
registered at ClinicalTrials.gov (NCT01291472, EudraCT 2011-000367-27).  
 
Patients, ketorolac dosing, sample collection and sample handling  
Enantiomer-specific ketorolac PK were calculated in women shortly following caesarean 
delivery. A subgroup of these women was planned to be re-evaluated in later postpartum period 
(‘postpartum’) and there was another cohort of healthy female volunteers. 
An IV bolus of 30 mg ketorolac tromethamine (Taradyl®, Roche, Anderlecht, Belgium), equal to 
20.345 mg of pure ketorolac (67%), was administered to all women. For women shortly 
following caesarean delivery, ketorolac was administered as part of multimodal analgesia in the 
University Hospitals Leuven, Belgium [24]. Except for the locoregional anesthetics and IV 
paracetamol administered as part of the multimodal analgesia following caesarean delivery, those 
women used no other medications for at least 48 hours before and during the study.  
In a subgroup of those women who were re-evaluated in postpartum and in healthy female 
volunteers, an IV bolus of 30 mg ketorolac tromethamine was administered as a single dose. 
Those women also used no other medications for at least 48 hours before and during the study. 
To all women, ketorolac was administered as a slow injection over 30 seconds through a 
peripherally inserted venous cannula in the hand of the patient. Five blood samples (i.e. at 1, 2, 4, 
6 and 8 hours post dose were collected from a second peripheral venous cannula, dedicated for 
study related sampling only. Blood samples were collected in lithium heparinized tubes, 
Page 7 of 26 
centrifuged and plasma was stored at -20 °C until analysis. Plasma concentrations of S- and R-
ketorolac were determined using a validated high performance liquid chromatography (HPLC) 
analysis with UV detection after extraction procedure based on solid-phase extraction [25].  
 
Pharmacokinetics  
Main outcome measures were individual enantiomer-specific PK parameters. These were 
calculated using PKSolver, a program for pharmacokinetic and pharmacodynamic data analysis 
in Microsoft Excel [26]. We hereby assumed a noncompartimental model for IV bolus. Area 
under the curve (AUC(0-∞), mg·h/L), elimination half-life (t1/2, h), distribution volume at steady 
state (Vss), distribution volume at steady state corrected for body weight (Vss/BW, L/kg), 
clearance (CL), clearance corrected for body weight (CL/BW, L/h·kg) and clearance corrected 
for body surface area (CL/BSA, L/h·m2) were calculated, with BSA calculated by the following 
formula: BSA (m2)=0.024265 ·  body height (cm)0.3964 ·  body weight (kg)0.5378 [27]. To compare 
changes in clearance between enantiomers, the ratio of S/R-ketorolac CL/BSA was also 
calculated and compared between cohorts. 
 
Statistics 
Data were compared using the Kruskal-Wallis test for unpaired comparisons, the Wilcoxon 
signed ranks signed test for paired comparisons and explored using Spearman correlation 
(MedCalc, Mariakerke, Belgium). A p value <0.05 was considered statistically significant. 
Results were reported by median and range. 
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RESULTS  
Forty-seven women and 235 time-concentration profiles were included in the current study.  
 
Women shortly following caesarean delivery vs postpartum vs healthy female volunteers, Table 1 
 
When observations in women shortly following caesarean delivery (excluding eight women who 
were re-evaluated in postpartum, n=31) were compared to similar observations in women in 
postpartum (mean 21th, 17.1-22.6th postpartum week) (n=8) or healthy female volunteers (n=8), 
the observed Cmax was significantly lower for both S- and R-ketorolac in women shortly 
following caesarean delivery compared to those in postpartum women or healthy female 
volunteers. As anticipated from the observed Cmax, the median Vss for both S- and R-ketorolac 
were significantly higher shortly following caesarean delivery compared to those in postpartum 
women and in healthy female volunteers. When corrected for BW, median Vss for both S- and 
R-ketorolac were significantly higher in women shortly following caesarean delivery compared 
to those in healthy female volunteers. 
Median CL, CL/BW and CL/BSA for both S- and R-ketorolac were significantly higher in 
women shortly following caesarean delivery compared to those in postpartum women and in 
healthy female volunteers (Figure 1 and 2).  
The ratio of S/R-ketorolac CL/BSA was significantly higher in women shortly following 
caesarean delivery compared to this value in postpartum women (Figure 3).  
No difference in median elimination half-life was documented between the three groups (Table 
1). 
 
Page 9 of 26 
Women shortly following caesarean delivery vs postpartum (paired analysis), Table 2 
 
When comparing the pharmacokinetic estimates in the eight paired cases, i.e. women shortly 
following caesarean delivery and the same women in postpartum (mean 21th, 17.1-22.6th 
postpartum week), the observed Cmax for both S- and R-ketorolac were significantly lower 
shortly following caesarean delivery compared to the postpartum period. 
No differences either in Vss or Vss/BW were found for S-ketorolac while median Vss for R-
ketorolac was significantly higher shortly following caesarean delivery compared to those in 
postpartum of the same women.  
CL and CL/BSA for both S- and R-ketorolac were significantly higher shortly following 
caesarean delivery compared to those in postpartum of the same women. In addition, for S-
ketorolac, median CL/BW was also significantly higher shortly following caesarean delivery 
compared to this in postpartum.  
The ratio of S/R-ketorolac CL/BSA was not different shortly following caesarean delivery 
compared to this in postpartum of the same women. No difference in median elimination half-
life was documented between these two physiological states of the same women (Table 2). 
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DISCUSSION 
To our best knowledge, the current paper is the first report on the impact of pregnancy and 
postpartum on enantiomer-specific pharmacokinetics of IV ketorolac. Significant differences in 
median pharmacokinetic estimates in women shortly following caesarean delivery compared to 
those in postpartum women and in healthy female volunteers were documented.  
As anticipated, higher BW and BSA in women shortly following caesarean delivery compared to 
those in postpartum (Table 1). However, even after taking these body size differences into 
account, clearance of both S- and R-ketorolac were shown to be higher in women shortly 
following caesarean delivery compared to observations in postpartum (mean 21th week) (S-
ketorolac: +33.3%, L/h·kg, +38.6%, L/h·m2; R-ketorolac: +33.3%, L/h·kg, +31.4%, L/h·m2) and 
in healthy female volunteers (S-ketorolac: +33.3%, L/h·kg, +48.4%, L/h·m2; R-ketorolac: 
+33.3%, L/h·kg, +56.8%, L/h·m2) (Table 1, Figure 1 and 2).  
 
The ratio of S/R-ketorolac CL/BSA reflects the difference in changes of the enantiomer-specific 
clearances (S or R). Interestingly, S/R-ketorolac CL/BSA was significantly higher in women 
shortly following caesarean delivery compared to this in postpartum women (Figure 3). As 
mentioned earlier, enantiomer-specific pharmacokinetic differences may be explained by 
stereoselective binding to plasma albumin [7,8]. Lower albumin binding for S- than for R-
ketorolac [3] with additional lower protein binding due to pregnancy induced hypoalbuminemia  
[9,28] result in even higher free concentrations of S- compared to R-ketorolac. This, at least in 
part, may explain the impact of pregnancy on the S/R-ketorolac ratio.  
The impact of pregnancy on the S/R-ketorolac ratio is of pharmacodynamic relevance, since this 
means that S clearance is somewhat more increased to R clearance in women shortly following 
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caesarean delivery. Since the analgesic effect of ketorolac relates exclusively to S-ketorolac, it is 
reasonable to assume that the analgesia will disappear earlier shortly following caesarean 
delivery compared to postpartum. 
 
The additional paired PK analysis in eight women following ceasarean delivery and in their later 
postpartum confirmed this pattern. Finally, the simultaneous increase in CL and Vss resulted in 
similar estimates for elimination half-life in both unpaired and paired analysis. 
 
As for other analgesics, a single dose of ketorolac can be applied, making Cmax a relevant 
parameter for the therapeutic effect [29]. As anticipated from our results, increased ketorolac Vss 
in women shortly following caesarean delivery resulted in Cmax to be significantly lower 
compared to that in postpartum women (-40.0% for S-ketorolac and -36.2% for R-ketorolac), as 
well as when compared to that in healthy female volunteers (-43.2% for S-ketorolac and -44.4% 
for R-ketorolac).  
 
The current enantiomer-specific pharmacokinetics confirm the previous reported impact of 
physiological changes in pregnancy and postpartum on racemic ketorolac pharmacokinetics 
[21,23,30,31]. Distribution volume of racemic ketorolac was 40% and clearance was 50% higher 
in post-caesarean women compared to those in healthy female volunteers [21]. This was also 
confirmed by paired analysis which showed distribution volume of racemic ketorolac in post-
caesarean women to increase 40-50% and total clearance to increase 30-40% compared to those 
in 4-5 months postpartum of the same women [21].  
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It is known that compared to non-pregnant state of adult women, pregnancy is, besides lower 
protein binding due to hypoalbuminemia, also characterized by a higher fractional volume of 
body water [9,28]. In addition, a 3-7% decrease in plasma protein binding was documented to 
double volume of distribution of ketorolac [32]. Having in mind that ketorolac is also a low-
extraction drug [2,32], its hepatic clearance [33] is directly proportional to its unbound fraction 
in plasma [34]. This likely explains the higher clearance and distribution volume for racemic 
ketorolac [30,31] and both ketorolac enantiomers in women shortly following caesarean delivery 
compared to those in postpartum and in healthy female volunteers. Proportional change in 
clearance and distribution volume results in no change in ketorolac half-life as documented in 
this study.  
 
As documented after IV ketorolac administration in children [8,10,11] and after all ketorolac 
administration routes in non-pregnant women and men [3,35], the same pattern of clearance and 
distribution volume (Table 3), both being higher for pharmacologically active S- compared to R-
ketorolac [10,11] was also confirmed in each cohort of the current study. S-ketorolac clearance 
[6,33] and distribution volume [11] are also shown to be age-dependent (i.e. higher in children 
compared to adults). The age range in our study was limited to young adulthood (25-44 years). 
 
This study certainly has its limitations. Firstly, due to the vulnerability of the postpartum period, 
the sample size of those women was limited but still allowed us to perform reliable paired 
analysis. Secondly, according to some authors, a time course followed for only 8 hours might 
cause an underestimation of the true half-life [2]. However, the 8 hours time interval in our study 
was initially based on the clinical practice of post caesarean delivery ketorolac administration 
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(q8h) in our hospital [31]. In addition, the present study showed the 8 hours interval to represent 
a minimum of 2 half-life values for R-ketorolac and a minimum of 3-4 half-life values for S-
ketorolac in all cohorts evaluated.  
 
The fact that only one of the ketorolac enantiomers has analgesic effects makes enantiomer-
specific pharmacokinetics of clinical relevance and does illustrate the need to explore the 
enantiomer-specific pharmacokinetic/pharmacodynamic relation. Additionaly, taking the 
different physiological states of women life and factors other than pharmacokinetics that can 
influence pharmacodynamics into account, we suggest to reconsider the current dosing regimens. 
This means that, due to pharmacokinetic changes during pregnancy, extrapolation of dosing 
regimens from results obtained in adult women should be done with caution in women following 
delivery. To achieve therapeutic plasma concentrations, higher distribution volume in women 
following delivery suggests an initial loading dose. Furthermore, the body weight-adjusted 
maintenance doses of ketorolac could be higher in women following delivery compared to 
postpartum and non-pregnant/non-postpartum women, and could be applied by higher 
intermittent dosing or more frequent administration.  
 
Documented pharmacokinetic differences and quite extensive enantiomer-specific ketorolac 
pharmacokinetic variability among young women illustrate the relevance to perform 
pharmacokinetic studies in different states of adult women's life and confirm our earlier 
observations on intravenous paracetamol [36]. For definitive physiological state-specific dosing 
recommendations in women, we encourage future repeated dosing pharmacokinetic studies in 
this specific population.  
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CONCLUSION  
In conclusion, pregnancy affects S-, R-, and S/R-ketorolac disposition. This is of clinical 
relevance, since S-ketorolac (analgesia) CL is higher in women shortly following ceasarean 
delivery compared to postpartum or healthy female volunteers and this increase is even higher 
for S-CL compared to R-CL (S/R CL ratio).  
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TABLE 1. Clinical data and pharmacokinetic estimates for S- and R-ketorolac (IV ketorolac 
single-dose) following caesarean delivery, in postpartum and in healthy female volunteers 
 
 Women shortly 
following 
caesarean delivery 
n=31a  
Postpartum 
women 
n=8  
Healthy female 
volunteers, n=8  
p-value  
 
Age (y) 33 (25-44) 31.5 (25-35) 32.5 (28-43) 0.376 
Body weight (kg) 73.20 (40-106) 60.75 (49-87) 62.75 (56-69) 1≠2,3; *0.035; **0.004 
Body surface area (BSA, m2) 1.82 (1.29-2.26) 1.66 (1.48-2.01) 1.69 (1.57-1.82) 1≠2,3; *0.026; **0.015 
S-ketorolac pharmacokinetic parameters    
Cmax (mg/L) 0.42 (0.22-0.63)  0.70 (0.40-1.13)  0.74 (0.61-1.08) 1≠2,3; **<0.001; **<0.001 
AUC(0-∞) (mg·h/L)  1.56 (0.87-3.00) 2.73 (1.69-4.53) 2.88 (2.22-4.51) 1≠2,3; **<0.001; **<0.001 
t1/2 (h) 1.84 (0.98-3.32) 1.88 (1.64-2.87) 2.15 (1.60-3.38) 0.181 
Vss (L) 12.79 (5.79-30.39) 7.84 (4.82-15.89) 9.14 (6.07-11.53) 1≠2,3; *0.011; **0.002 
Vss/BW (L/kg) 0.18 (0.08-0.43) 0.11 (0.07-0.27) 0.15 (0.10-0.18) 1≠3; *0.037 
CL (L/h) 6.49 (3.39-11.68) 3.73 (2.24-6.02) 3.60 (2.26-4.58) 1≠2,3; **<0.001; **<0.001 
CL/BW (L/h·kg)  0.09 (0.05-0.19) 0.06 (0.04-0.10) 0.06 (0.04-0.07) 1≠2,3; **0.005; **<0.001 
CL/BSA (L/h·m2) 3.47 (1.89-6.67) 2.13 (1.40-3.97) 2.06 (1.43-2.62) 1≠2,3; **0.002; **<0.001 
R-ketorolac pharmacokinetic parameters 
Cmax (mg/L) 0.90 (0.48-1.16) 1.41 (0.91-2.00) 1.62 (1.36-1.93) 1≠2,3; **0.001; **<0.001 
AUC(0-∞) (mg·h/L)  4.76 (2.90-9.30) 7.10 (5.14-11.20) 10.26 (6.56-14.03) 1≠2,3; **0.002; **<0.001 
2≠3; *0.046 
t1/2 (h) 3.11 (1.58-6.20) 3.23 (2.37-4.80) 3.51 (2.55-7.36) 0.306 
Vss (L) 8.96 (5.51-16.34) 5.86 (4.09-8.65) 5.51 (4.40-6.89) 1≠2,3; **0.001; **<0.001 
Vss/BW (L/kg) 0.12 (0.09-0.23) 0.09 (0.06-0.15) 0.09 (0.07-0.12) 1≠3; **0.001 
CL (L/h) 2.14 (1.09-3.51) 1.43 (0.91-1.98) 0.99 (0.73-1.55) 1≠2,3; **0.002; **0.001 
2≠3; *0.046 
CL/BW (L/h·kg)  0.03 (0.02-0.06) 0.02 (0.02-0.03) 0.02 (0.01-0.02) 1≠2,3; *0.044; **<0.001 
2≠3; *0.016 
CL/BSA (L/h·m2) 1.18 (0.65-1.87) 0.81 (0.57-1.30) 0.59 (0.43-0.89) 1≠2,3; *0.012; **<0.001 
2≠3; *0.021 
S/R ratio 
S/R CL/BSA 3.07 (1.91-4.97) 2.73 (2.12-3.05) 3.11 (2.47-4.36) 1≠2; *0.020 
aexcluding eight women who were reevaluated again in later postpartum to ensure unpaired analysis. 
All values were reported as median (minimum-maximum). Kruskal-Wallis test was used to compare the data. 
p<0.05 was considered to be statistically significant (*p<0.05; **p<0.01). 
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TABLE 2. Clinical data and pharmacokinetic estimates for S- and R-ketorolac (IV ketorolac 
single-dose) in the group of the same eight women following caesarean delivery and in 
postpartum  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All values were reported as median (minimum-maximum). Paired Wilcoxon ranks signed test was used to compare 
the data. p<0.05 was considered to be statistically significant (*p<0.05; **p<0.01). 
 
 
 
 
 
 
 
 
 
 
 Women shortly 
following 
caesarean delivery 
n=8 
Postpartum 
women 
n=8 
p-value 
 
Body weight (kg) 75.50 (60-85) 60.75 (49-87) *0.017 
Body surface area (BSA, m2) 1.89 (1.65-1.98) 1.66 (1.48-2.01) *0.017 
S-ketorolac pharmacokinetic parameters 
Cmax (mg/L) 0.41 (0.26-0.60)  0.70 (0.40-1.13)  *0.036 
AUC(0-∞) (mg·h/L)  1.51 (1.32-2.40) 2.73 (1.69-4.53) *0.012 
t1/2 (h) 2.18 (1.26-2.58) 1.88 (1.64-2.87) 0.674 
Vss (L) 12.22 (8.92-16.86) 7.84 (4.82-15.89) 0.093 
Vss/BW (L/kg) 0.18 (0.14-0.22) 0.11 (0.07-0.27) 0.327 
CL (L/h) 6.76 (4.24-7.73) 3.73 (2.24-6.02) *0.012 
CL/BW (L/h·kg)  0.09 (0.05-0.11) 0.06 (0.04-0.10) *0.036 
CL/BSA (L/h·m2) 3.81 (2.14-4.09) 2.13 (1.40-3.97) *0.025 
R-ketorolac pharmacokinetic parameters 
Cmax (mg/L) 0.87 (0.74-1.08)  1.41 (0.91-2.01)  *0.017 
AUC(0-∞) (mg·h/L)  4.80 (3.20-7.79) 7.10 (5.14-11.20) *0.017  
t1/2 (h) 3.39 (1.90-4.89) 3.23 (2.37-4.80) 0.779 
Vss (L) 8.42 (6.64-10.41) 5.86 (4.09-8.65) *0.017 
Vss/BW (L/kg) 0.13 (0.10-0.14) 0.09 (0.06-0.15) 0.069 
CL (L/h) 2.15 (1.31-3.17) 1.43 (0.91-1.98) *0.017 
CL/BW (L/h·kg)  0.03 (0.02-0.04) 0.02 (0.02-0.03) 0.069 
CL/BSA (L/h·m2) 1.20 (0.66-1.61) 0.81 (0.57-1.30) *0.025 
S/R ratio    
S/R CL/BSA 3.09 (2.28-3.99) 2.73 (2.12-3.05) 0.123 
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TABLE 3. Clinical data, intravenous (IV) dose administered, and clearance (CL) and 
distribution volume (Vd) estimates for S- and R-ketorolac in different populations studied  
 
Population Age, 
years  
Body 
weight, kg 
IV 
dose, 
mg/kg 
S-ketorolac R-ketorolac References 
CL, 
mL/min·kg 
Vd,  
L/kg 
CL,  
mL/min·kg 
Vd, L/kg 
Children 
n=11 
1.7-15.6 10.7-67.4 0.5  
 
2.98 L/h 13.2 L 1.5 L/h 8.2 L Mohammed BS 
et al, 2015 
Infants 
n=10, n=20 
2.2-18 
months 
NA 0.5  
1  
5.1±4.3  0.45±0.33 0.95±0.54 
 
0.27±0.17 Lynn  
et al, 2010 
Children 
n=18 
8.1±1.5 
 
31±7 0.5  66.8±13.8 
mL/h·kg 
0.715±0.415 21.1±4.9 
mL/h·kg 
0.155±0.034 Hamunen  
et al,1999 
Children  
n=47 
11.7 NA 0.6 6.2±3.3 
 
0.82±0.38 
 
1.4±0.5 
 
0.50±0.34 Kaufmann  
et al, (1998) 
Adolescents 
n=18 
14.2±1.7 
 
54±11 0.5  66.2±17.5 
mL/h·kg 
0.442±0.305 21.4±5.9 
mL/h·kg 
0.141±0.030 Hamunen  
et al, (1999) 
Adults 
n=18 
31.3±7.4 
 
72±12 0.5  57.7±11.0 
mL/h·kg 
0.282±0.140 22.2±4.3 
mL/h·kg 
0.129±0.022 Hamunen  
et al, (1999) 
Healthy 
volunteer 
45 74 10 0.020 
L/h·kg 
0.062 0.019 
L/h·kg 
0.066 Brocks DR and 
Jamali F, 1992 
Healthy  
adults, n=9 
NA NA 10 mg 0.660±0.114  0.140±0.021 0.280±0.059  0.109±0.016 Mroszczak et 
al, 1996 
All clearance and distribution volume values were reported as mean, mean±standard deviation or mean [range] 
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Figure legends 
 
FIGURE 1. Unpaired comparison of (a) S-ketorolac clearance (L/h) and (b) R-ketorolac 
clearance (L/h) in women shortly following caesarean delivery vs. postpartum women vs. healthy 
female volunteers 
 
FIGURE 2. Unpaired comparison of (a) S-ketorolac clearance (L/h·m2) corrected for body 
surface area (BSA) and (b) R-ketorolac clearance (L/h·m2) corrected for BSA in women shortly 
following caesarean delivery vs. postpartum women vs. healthy female volunteers 
 
FIGURE 3. Unpaired comparison of the ratio of S and R-ketorolac clearance (L/h·m2) corrected 
for body surface area (BSA) in women shortly following caesarean delivery vs. postpartum 
women vs. healthy female volunteers 
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FIGURE 1. a, b 
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FIGURE 2. a. b 
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FIGURE 3.  
 
 
 
  
 
